A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers
James V Cassella, Daniel A Spyker, Paul P Yeung, James V Cassella, Daniel A Spyker, Paul P Yeung
Abstract
Objective: This randomized, double-blind, active- and placebo-controlled, crossover, thorough QT study assessed the effect of two inhaled loxapine doses on cardiac repolarization as measured by corrected QT (QTc) interval in healthy subjects (ClinicalTrials.gov NCT01854710).
Methods: Subjects received two doses of inhaled loxapine (10 mg) 2 hours apart+oral placebo, two doses of inhaled placebo+oral placebo, or two doses of inhaled placebo+oral moxifloxacin (400 mg; positive control), with ≥3 days washout between treatments. Two-sided 90% confidence intervals (CIs) were calculated around least-squares mean predose placebo-subtracted individually corrected QT durations (ΔΔTcIs) at 12 time points throughout 24 hours after dosing. A ΔΔTcI 95% upper CI exceeding 10 msec was the threshold indicating QTc prolongation (primary endpoint). Secondary endpoints included Fridericia- and Bazett-corrected QT duration and QTcI outliers. Pharmacokinetics and adverse events (AEs) were also assessed.
Results: Of 60 subjects enrolled (mean age, 33.8 years; 52% male), 44 completed the study. Post loxapine dosing, no ΔΔTcI 95% upper CI exceeded 10 msec; the largest was 6.31 msec 5 minutes post dose 2. Methodology was validated by ΔΔTcI 95% lower CIs exceeding 5 msec at 9 of 12 time points after moxifloxacin dosing. Loxapine plasma concentrations increased rapidly (mean Cmax, 177 ng/mL; median tmax 2 minutes after dose 2, 2.03 hours after dose 1). There were no deaths, serious AEs, or AEs leading to discontinuation, and one severe AE.
Conclusions: Primary and secondary endpoints indicated two therapeutic doses of inhaled loxapine did not cause threshold QTc prolongation in this study.
Figures
References
- Heel RC Brogden RN Speight TM Avery GS Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978; 15: 198–217.
- Kapur S Zipursky R Remington G Jones C McKay G Houle S PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997; 154: 1525–1529.
- Allen MH Feifel D Lesem MD Zimbroff DL Ross R Munzar P Spyker DA Cassella JV Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72: 1313–1321.
- Lesem MD Tran-Johnson TK Riesenberg RA Feifel D Allen MH Fishman R Spyker DA Kehne JH Cassella JV Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011; 198: 51–58.
- Kwentus J Riesenberg RA Marandi M Manning RA Allen MH Fishman RS Spyker DA Kehne JH Cassella JV Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14: 31–40.
- Spyker DA Munzar P Cassella JV Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010; 50: 169–179.
- Glassman AH Bigger JT Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158: 1774–1782.
- Hasnain M Vieweg WV QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014; 28: 887–920.
- Crumb WJ Ekins S Sarazan RD Wikel JH Wrighton SA Carlson C Beasley CM Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006; 23: 1133–1143.
- Kongsamut S Kang J Chen XL Roehr J Rampe D A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002; 450: 37–41.
- International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist. 2005; 70: 61134–61135.
- Spyker DA Voloshko P Heyman ER Cassella JV Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014; 54: 665–674.
- Dinh K Myers DJ Glazer M Shmidt T Devereaux C Simis K Noymer PD He M Choosakul C Chen Q Cassella JV In vitro aerosol characterization of Staccato( ) Loxapine. Int J Pharm. 2011; 403: 101–108.
- Zhang J Machado SG Statistical issues including design and sample size calculation in thorough QT/QTc studies. J Biopharm Stat. 2008; 18: 451–467.
- Shah RR Morganroth J Kleiman RB ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies. Br J Clin Pharmacol. 2015; 79: 456–464.
- . and . accessed Oct 2014.
- Drolet B Zhang S Deschênes D Rail J Nadeau S Zhou Z January CT Turgeon J Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol. 1999; 10: 1597–1604.
- Pae CU Sertindole: dilemmas for its use in clinical practice. Expert Opin Drug Saf. 2013; 12: 321–326.
- Peterson CD Seizures induced by acute loxapine overdose. Am J Psychiatry. 1981; 138: 1089–1091.
- Roberge RJ Martin TG Mixed fluoxetine/loxapine overdose and atrial flutter. Ann Emerg Med. 1994; 23: 586–590.
- Mazzola CD Miron S Jenkins AJ Loxapine intoxication: case report and literature review. J Anal Toxicol. 2000; 24: 638–641.
- Baker SN Management of acute agitation in the emergency department. Adv Emerg Nurs J. 2012; 34: 306–318.
- Sharma ND Rosman HS Padhi ID Tisdale JE Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998; 81: 238–240.
- . accessed Sep 2014.
- Gross N Greos LS Meltzer EO Spangenthal S Fishman RS Spyker DA Cassella JV Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease – two randomized controlled trials. J Aerosol Med Pulm Drug Deliv. 2014; 27: 478–487.
Source: PubMed